Verona Pharma plc Pdmr Dealing
March 07 2019 - 3:14AM
UK Regulatory
TIDMVRP
LONDON, March 07, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP)
(Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical
company focused on developing and commercializing innovative therapies
for respiratory diseases, announces that, on March 6, 2019, Dr. David
Ebsworth, Chairman of the Company, purchased 26,300 ordinary shares of 5
pence each in the Company (the "Ordinary Shares") at a price of 56.30
pence per Ordinary Share and a total purchase price of GBP14,806.90
Following the acquisition, Dr. Ebsworth will have an interest in the
Company of 217,887 Ordinary Shares, representing 0.21% of the Company's
issued share capital.
The notification set out below is provided in accordance with the
requirements of the EU Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities/person
closely associated
----------------------------------------------------------------------
a) Name David Ebsworth
----------------------------------------- ---------------------------
2 Reason for the notification
----------------------------------------------------------------------
a) Position/status Chairman
----------------------------------------- ---------------------------
b) Initial notification/Amendment Initial notification
----------------------------------------- ---------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name Verona Pharma plc
----------------------------------------- ---------------------------
b) LEI 213800EVI6O6J3TIAL06
----------------------------------------- ---------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
--------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of instrument Ordinary Shares of 5 pence each
Identification code GB00BYW2KH80
----------------------------------------------------------- -------------------------------------------------
b) Nature of the transaction David Ebsworth purchased 26,300 Ordinary Shares
----------------------------------------------------------- -------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
----------------------------------------------------------- ----------------- ------------------------------
56.30 pence per 26,300 Ordinary Shares
Ordinary Share
----------------------------------------------------------- ----------------- ------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
----------------------------------------------------------- -------------------------------------------------
e) Date of the transaction 6 March 2019
----------------------------------------------------------- -------------------------------------------------
f) Place of the transaction London Stock Exchange, AIM
----------------------------------------------------------- -------------------------------------------------
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
Victoria Stewart, Director of Communications
Stifel Nicolaus Europe Limited (Nominated Adviser Tel: +44 (0) 20 7710 7600
and UK Broker)
Stewart Wallace / Jonathan Senior / Ben Maddison
(END) Dow Jones Newswires
March 07, 2019 03:14 ET (08:14 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024